Wells Fargo & Company Pharvaris N.V. Transaction History

Wells Fargo & Company

  • $507 Billion
  • Q3 2025

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
BUY
$11.83 - $18.66 $591 - $933
50 Added 5.26%
1,000 $17,000
Q1 2025

May 13, 2025
BUY
$14.9 - $19.54 $2,235 - $2,931
150 Added 18.75%
950 $14,000
Q3 2024

Nov 13, 2024
BUY
$15.73 - $21.4 $1,573 - $2,140
100 Added 14.29%
800 $14,000
Q2 2024

Aug 13, 2024
BUY
$15.67 - $24.59 $10,969 - $17,213
700 New
700 $13,000

Others Institutions Holding PHVS

# of Institutions
81
Shares Held
51M
Call Options Held
0
Put Options Held
0
View Full List

About Pharvaris N.V.

PHVS Quotes by TradingView
  • Ticker PHVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,766,000
  • Market Cap $795M
  • Description
  • Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...
More about PHVS
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email